GCG and metabolic dysfunction-associated steatotic liver disease: In summary, these results indicate that CGA protects against HFD-induced hepatic steatosis and inflammation probably through its anti-inflammatory effects associated with regulation of certain gut microbiota and an increase of GLP-1 secretion and thus can be used as a potential drug for the prevention and treatment of NAFLD.